Marais A, Monteiro L, Occhialini A, Pina M, Lamouliatte H, Mégraud F
Laboratoire de Bactériologie, Université Victor Ségalen Bordeaux 2 et Hôpital Pellegrin, 33076 Bordeaux cedex, France.
Gut. 1999 Apr;44(4):463-7. doi: 10.1136/gut.44.4.463.
The increasing use of macrolides especially in the treatment of Helicobacter pylori infection has led to an increase in resistant strains. The resistance of H pylori to macrolides, especially clarithromycin, is one of the major causes of eradication failure. In H pylori, clarithromycin resistance is due to point mutations localised in domain V of 23S rRNA.
To develop a molecular technique based on amplification of a relevant fragment of the 23S rRNA and colorimetric hybridisation in liquid phase to detect directly in biopsy specimens the type of mutation associated with resistance of H pylori to clarithromycin.
Gastric biopsy samples from 61 patients were submitted to this test. The results were compared with standard methods (determination of minimal inhibition concentration, polymerase chain reaction/restriction fragment length polymorphism, and/or DNA sequencing) in order to evaluate the test and to define the cut off values, specificity, and sensitivity.
The 14 biopsy samples in which H pylori was not detected did not give a positive result in any assay, and the 14 samples harbouring strains susceptible to clarithromycin gave a positive result with the wild type probe as expected. The 33 biopsy specimens containing resistant strains always gave a positive signal with one of the probes detecting resistant organisms, but in eight cases they also reacted with the wild type probe, indicating that a mixture of resistant and susceptible organisms was present.
The importance of this new assay is that it allows the detection of multiple genotypes corresponding to either heterogeneous genotypes or mixed infections. Moreover, it allows in a single step not only the detection of H pylori but also the determination of its susceptibility to clarithromycin directly in biopsy specimens without the need for culture.
大环内酯类药物的使用日益增加,尤其是在幽门螺杆菌感染的治疗中,这导致了耐药菌株的增多。幽门螺杆菌对大环内酯类药物,尤其是克拉霉素的耐药性是根除治疗失败的主要原因之一。在幽门螺杆菌中,克拉霉素耐药性是由于23S rRNA结构域V中的点突变所致。
开发一种基于23S rRNA相关片段扩增和液相比色杂交的分子技术,以直接在活检标本中检测与幽门螺杆菌对克拉霉素耐药相关的突变类型。
对61例患者的胃活检样本进行该检测。将结果与标准方法(最低抑菌浓度测定、聚合酶链反应/限制性片段长度多态性分析和/或DNA测序)进行比较,以评估该检测方法并确定临界值、特异性和敏感性。
14份未检测到幽门螺杆菌的活检样本在任何检测中均未给出阳性结果,14份含有对克拉霉素敏感菌株的样本如预期那样与野生型探针给出阳性结果。33份含有耐药菌株的活检标本总是与检测耐药菌的探针之一给出阳性信号,但在8例中它们也与野生型探针发生反应,表明存在耐药菌和敏感菌的混合情况。
这种新检测方法的重要性在于它能够检测对应于异质基因型或混合感染的多种基因型。此外,它不仅可以在一步操作中直接在活检标本中检测幽门螺杆菌,还能确定其对克拉霉素的敏感性,而无需进行培养。